QHRD107 capsule，Venclexta and Azacitidine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)

Drug Information

Target Indication

Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)

Clinical Trial

Last updated: 1/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BIOE

Bio Essence Corp

Related Pipeline

Anemia in Incident Dialysis Patients

Benign Prostatic Hyperplasia

Geographic Atrophy

Psoriatic Arthritis

Congenital Rubella Infection